FourKites Expands Executive Leadership Team with Bo Tao, Chief Technology Officer, and Manik Mair, SVP Corporate Growth
27.7.2023 12:12:00 EEST | Business Wire | Press release
Leading supply chain visibility provider FourKites today announces it has expanded its leadership team with two seasoned executives: Chief Technology Officer Dr. Bo Tao and Senior Vice President of Corporate Growth Manik Mair. These recent executive additions come at a time of rapid customer expansion and global company growth, as FourKites doubles down on its mission to deliver supply chain visibility everywhere, and its unwavering commitment to customer success.
Dr. Bo Tao, CTO, will drive product innovation across FourKites’ technology portfolio with a particular focus on artificial intelligence and machine learning, as well as customer-led product growth. Tao is an experienced engineering leader and an industry veteran, having worked in the logistics and software industry for over 20 years. His expertise spans full-stack development, machine learning and data engineering, with experience at NEXT Trucking, Google, Symantec, Dell Technologies and Cheetah Mobile. Tao holds 10 patents, as well as a PhD from Princeton University.
“Through the integration work my Next Trucking team did with FourKites, I experienced firsthand the value that FourKites’ solutions brought not only to that business but also to the entire supply chain ecosystem,” says Tao. “Now, as FourKites’ CTO, my goal is to create a holistic technology landscape that delivers the best possible results, while simultaneously focusing on engineering excellence, execution and building for scale to accommodate our rapidly growing customer base.”
Manik Mair, SVP of Corporate Growth, is responsible for defining and implementing FourKites’ corporate growth agenda across all domains, functions and regions. An experienced software executive and business strategist, Mair was most recently the Global Vice President, Head of GTM Strategy, at Ceridian (NYSE:CDAY), where he helped define and implement the go-to-market strategy across all regions, offerings and channels. Prior to that, Mair was part of EY’s strategy consulting practice, where he focused on corporate, portfolio and business unit strategy, digital transformation and go-to-market strategy.
“FourKites’ visionary approach and ceaseless innovation continually push the boundaries of what’s possible, delivering transformational value to our customers,” says Mair. “I’m thrilled to join the team, not only to build robust, cross-functional growth capabilities, but also to support FourKites’ increasing focus on helping our customers grow effectively and efficiently.”
“Customer-led innovation and product growth have been ingrained in our company’s DNA since our inception, and remain so as we continue to grow,” says FourKites founder and CEO Mathew Elenjickal. “Bo’s and Manik’s commitment to customer success and innovation exemplify what we value most at FourKites, and we are thrilled to have them join our team.”
FourKites’ leadership expansion highlights the company’s strong, sustained growth across the globe. Earlier this month, the company announced the expansion of its teams dedicated to driving innovation for key verticals, and helping customers maximise the value they derive from the platform. Over the last 12 months, the company has experienced nearly 40% YoY increase in customers, as well as nearly 40% growth in the number of shipments tracked in the FourKites platform — across 95% of the world’s ports and more than 200 countries and territories. FourKites’ carrier network now totals 530,000+, with nearly 1 million downloads of FourKites’ CarrierLink mobile app.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727768190/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
